Apieron is very pleased to announce the clearance of the Insight™ eNO System by the U.S. Food and Drug Administration. The Insight eNO System measures exhaled nitric oxide (eNO) which is a well established indicator of airway inflammation in asthma. The Insight system is a highly accurate device, expressly designed for the physician’s office. It is non-invasive, safe, easy to use, and provides eNO results in less than a minute. Apieron’s unique biosensor detects trace amounts of nitric oxide molecules in a single human breath utilizing a proprietary technology.

Current methods and techniques used to diagnose, monitor and manage asthma do not measure airway inflammation, which is the primary pathogenic process leading to the signs and symptoms of asthma. The addition of eNO to the standard asthma management tools allows a window into the inflammatory process occurring in the airways that can help improve asthma control. Physician office measurement of eNO is a much awaited breakthrough in medical technology that provides physicians with a reliable tool to measure airway inflammation as an adjunct to the current diagnostic measures, e.g. lung function. Exhaled nitric oxide has been established as a reliable marker of airway inflammation in asthma for over 10 years. Exhaled nitric has been the central focus of studies establishing its link to optimizing medication¹ and reflecting and predicting asthma control ^2,3,4.

Sales and Product Information
sales@apieron.com

Customer Care and Technical Support
1-866-550-4eNO  (1-866-550-4366)
Monday-Friday, 6 am - 6 pm (pacific time)
care@apieron.com

Investor and Public Relations
pr@apieron.com

Apieron Inc.
155 Jefferson Drive
Menlo Park, CA 94025

650-454-8100 Main Office
650-454-8190 Fax